Bibliography

1. Reading FC, Brecher ME. Transfusion-related bacterial sepsis. Curr Opin Hematol. 2001;8:380-386.
2. Dykstra A, Jacobs M, Yomtovian R. Prospective microbiologic surveillance (PMS) of random donor (RDP) and single donor apheresis platelets (SDP). Transfusion 1998;38(suppl):104S.
3. Blajchman MA, Vox Sang. 1998; 74(suppl 2):4-11.
4. Blajchman MA, Goldman M. Bacterial contamination of platelet concentrates: incidence, significance, and prevention. Semin Hematol. 2001;38:20-26.
5. Goldman M, Blajchman MA. Bacterial contamination, in Popovsky M (ed): Transfusion Reactions (ed 2). Bethesda, MD, American Association of Blood Banks, 2001: 133-159.
6. Leiby DA, Kerr KL, Compos JM, et al. A prospective analysis of microbial contaminants in outdated random-donor platelets from multiple sites. Transfusion 1997;37:259-263.
7. Barrett BB, Anderson JW, Anderson KC. Strategies for the avoidance of bacterial contamination of blood components. Transfusion 1993;133:228-233.
8. Yomtovian R, Lazarus HM, Goodnough LT, et al. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelet concentrates. Transfusion 1993;33:902-909.
9. Chiu EKW, Yuen KY, Lie AKW, et al. A prospective study on symptomatic bacteremia from platelet transfusion and its management. Transfusion 1994;34:950-965.
10. Blajchman MA, Ali A, Lyn P, et al. A prospective study to determine the frequency of bacterial contamination in random donor platelet concentrates. Blood 1994;84(suppl 1):529.
11. Blajchman MA, Ali A, Lyn P, et al. Bacterial surveillance of platelet concentrates: quantitation of bacterial load. Transfusion 1997;37(suppl):74s.
12. Liu H, Yuen K, Cheng T, et al. Reduction of platelet transfusion-associated sepsis by short term bacterial culture. Vox Sang. 1999; 77:1-5.
13. Blajchman MA, Ali AM. Bacteria in the blood supply: an overlooked issue in transfusion medicine, in Nance SJ (ed): Blood Safety: Current Challenges. Bethesda, MD, American Association of Blood Banks, 1992: 213-228.
14. Dzieczkowski JS, Barrett BB, Nester D, et al. Characterization of reactions after exclusive transfusion of white cell-reduced cellular blood components. Transfusion 1995;35:20-25.
15. Morrow JF, Braine HG, Kickler TS, et al. Septic reactions to platelet transfusions. JAMA 1991;266:555-558.
16. Jacobs MR, Palavecino E, Yomtovian R. Don't bug me: the problem of bacterial contamination of blood components -- challenges and solutions. Transfusion 2001;41:1331-1334.
17. Goldman M, Blajchman MA. Blood product-associated bacterial sepsis. Transfus Med Rev. 1991;5:73-83.
18. Love EM, Jones H, Williamson LM, et al on behalf of the SHOT Steering Group. Serious Hazards of Transfusion Annual Report 1999-2000. March 2001.
19. Noel L, Debeir J, Cosson A. The French haemovigilance system. Vox Sang. 1998;74(suppl 2):441-445.

20. Poiesz, BJ, Ruscetti, FW, Gazdar, AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci 1980; 77:7415.
21. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff RM, et al. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 1982;218:571-3.
22. Rizzetto M, Canese MG, Arico S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977 Dec;18(12):997-1003.
23. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
24. Reyes GR, Purdy MA, Kim JP, Luk KC, Young LM, Fry KE, Bradley DW. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science. 1990 Mar 16;247:1335-9.
25. Tam AW et al. Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology 1991;185(1):120-131.
26. Boneschi V, Brambilla L, Berti E, et al. Human herpesvirus 8 DNA in the skin and blood of patients with Mediterranean Kaposi's sarcoma: clinical correlations. Dermatology 2001;203:19-23.
27. Sheng L, Soumillion A, Beckers N, et al. Hepatitis G virus infection in acute fulminant hepatitis: prevalence of HGV infection and sequence analysis of a specific viral strain. Viral Hepat. 1998;5:301-306.
28. Parquet MC, Yatsuhashi H, Koga M, et al. Prevalence and clinical characteristics of TT virus (TTV) in patients with sporadic acute hepatitis of unknown etiology. Hepatol. 1999;31:985-989.
29. Umemura T, Tanaka E, Ostapowicz G, et al. Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. JID 2003; 188 (15 Nov): 1545-1552.
30. Bechter K, Bauer M, Estler HC, Herzog S, Schuttler R, Rott R. Expanded nuclear magnetic resonance studies in Borna disease virus seropositive psychiatric patients and control probands. Nervenarzt. 1994 Mar;65(3):169-74.
31. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003 May 15;348(20):1967-76.
32. http://www.cdc.gov/ncidod/dvbid/westnile/ (last visited 12/11/03).
33. Pealer LN, Marfin AA, Petersen LR, et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med. 2003 Sep 25;349(13):1236-45.
34. Hubalek Z, Halouzka J. West Nile fever — a reemerging mosquito-borne viral disease in Europe. Emerg Infect Dis. 1999;5:643-50.

35. Rueda A. Rethinking blood shield statutes in view of the hepatitis C pandemic and other emerging threats to the blood supply. J Health Law. 2001;34:419-458.
36. Dodd RY. Transmission of parasites by blood transfusion. Vox Sang. 1998;74(Suppl. 2):161-3.
37. Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med. 2001 Jun 28;344(26):1973-8.
38. Leiby DA, Herron RM Jr, Read EJ et al. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 2002;42(5):549-55.
39. Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and Human Immunodeficiency Virus coinfection: the first 10 years. Clin Microbiol Rev. 1997;10(2):298-319.
40. de Jong MD, Galasso GJ, Gazzard B, et al. Summary of the II International Symposium on cytomegalovirus. Antiviral Res. 1998;39(3):141-62.
41. Nichols WG, Price TH, Gooley T, et al. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003;101(10):4195-200.
42. Anderson LJ. Human Parvovirus B19: Incidence and Prevalence, in Richman DD, et al (ed): Clinical Virology (ed 1). New York, NY, Churchill Livingstone, 1997: 616-18.

43. Chamberland ME, Alter HJ, Busch MP, et al. Emerging infectious disease issues in blood safety. Emerg Infect Dis. 2001;7:552-553.
44. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42(8):975-9.

45. Anderson KC, Weinstein JH. Transfusion-associated graft-versus-host disease. N Engl J Med. 1990;323:315-321.
46. White DO, Fenner FJ. Medical Virology (4th edition). San Diego, CA, Academic Press Inc. 1994: 334-341.
47. Luban, NLC. Prevention of transfusion-associated graft-versus-host disease by inactivation of T cells in platelet components. Seminars in Hematology 2001;38(4)(Suppl 11):34-45.
48. Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998;91:2180-88.
49. Lin L. Inactivation of cytomegalovirus in platelet concentrates using Helinx^TM technology. Semin Hematol. 2001;38(4)(suppl 11):27-33.
50. Shanley JD. Human cytomegalovirus replicates in gamma-irradiated fibroblasts. J Med Virol 1986 Dec;20(4):347-55.

51. Honigsman H. Phototherapy for psoriasis. Clin Exp Dermatol 2001;26:343-350.
52. Gonzalez E. PUVA for psoriasis. Dermatol Clin 1995;13:851-866.
53. Bethea D, Fullmer B, Syed S, et al. Psoralen photobiology and photochemotherapy: 50 years of science and medicine. J Dermatol Sci 1999;19:78-88.
54. Gottlieb SL, Wolfe JT, Fox FE, et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: A 10-year experience at a single institution. J Am Acad Dermatol 1996;35:946-957.
55. Taylor A, Gasparro FP. Extracorporeal photochemotherapy for cutaneous T-cell lymphoma and other diseases. Semin Hematol 1992;29:132-141.
56. Lin L. Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997;37:423-35.
57. Lin L, Alfonso R, Behrman B, et al. Photochemical treatment of platelet concentrates with a novel psoralen and UVA to enhance the safety of platelet transfusions. Infusionstherapie Transfusionsmedizin. 1998;25:39-48.
58. Knutson F, Alfonso R, Dupuis K, et al. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang. 2000;78:209-16.

59. McCullough J, Vesole D, Benjamin RJ, et al. Pathogen inactivated platelets (plt) using Helinx^TM technology (INTERCEPT plt) are hemostatically effective in thrombocytopenic patients (tcp pts): The SPRINT trial. Blood. 2001;98:11,450a.
60. van Rhenen DJ, Gulliksson H, Pamphilon D, et al. S-59 (Helinx^TM) photochemically treated platelets (plt) are safe and effective for support of thrombocytopenia: results of the euroSPRITE phase 3 trial. Blood 2000;96:11:819a.
61. Ciaravino V, McCullough T, Dayan AD. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Human Exper Toxicol. 2001;20:533-550.
62. Ciaravino V. Preclinical safety of a nucleic acid-targeted Helinx^TM compound: a clinical perspective. Semin Hematol. 2001;38(suppl 11):12-19.